Optimizing Biospecimen Collection for CAR-T and Cell Therapy Research

Photo Credit: CDC/ Mildred Galton

Chimeric antigen receptor T cell (CAR-T) therapy has transformed oncology, turning once-fatal blood cancers into conditions many patients can manage long-term. But how well these living drugs work depends heavily on the quality of the starting biospecimens used throughout development. That holds true from target validation all the way through commercial manufacturing.

As the field expands beyond CD19-targeted blood cancers into solid tumors, autoimmune conditions, and infectious disease, the biospecimen supply chain becomes a critical factor. It affects both research speed and product quality.

Getting from patient-derived cells to a therapeutic-grade CAR-T product spans several phases, each with different biospecimen needs. Early discovery may use Human PBMCs from healthy donors to prove out a new CAR design. Process development needs larger-scale Human Leukopak preparations to optimize manufacturing and establish critical quality attributes.

At Sanguine, our portfolio spans this entire journey, enabling a smooth path from basic research through clinical manufacturing. It keeps quality standards and donor diversity consistent across the United States.

Discovery Phase: Target Validation and CAR Construct Optimization

CAR-T development starts by identifying tumor-associated targets and engineering receptors that recognize them with the right specificity and strength. This phase typically uses Human CD3+ T Cells isolated from healthy donor Human PBMCs to test CAR function in the lab.[1] Cell numbers stay modest — 5–20 million T cells per construct tested. But viability and function matter a lot, since researchers are screening dozens of CAR variants.

The mix of T cell subsets in the starting population significantly shapes the final CAR-T product. Naive T cells (CD45RA+CCR7+) expand and persist better in the body than fully differentiated effector cells, making their presence an important quality factor.[2] Central memory T cells (CD45RO+CCR7+) balance the ability to multiply with immediate effector function. Researchers optimizing CAR designs benefit from biospecimens with documented subset makeup. That lets them connect starting cell type to the final product’s characteristics.

Testing whether a CAR construct actually works requires target-expressing cell lines and patient-derived Human Plasma containing relevant soluble targets. Sometimes it also requires target-positive tumor cells for co-culture experiments. Human CD56+ NK Cells serve as controls, helping distinguish CAR-driven killing from ordinary natural killer cell activity.[3] Using this range of specimens gives a solid validation before moving to the more expensive process development stage.

Process Development: Manufacturing Protocol Optimization

Moving from discovery to process development means scaling up cell numbers while keeping product quality high. Human Leukopak products, collected by leukapheresis, provide the yields needed. A typical collection yields 1–5 × 10^10 total nucleated cells, enough for dozens of manufacturing runs from a single donor.[4] This scale supports testing different media, activation conditions, transduction parameters, and expansion protocols without donor-to-donor variability getting in the way.

Testing whether the process actually holds up requires biospecimens that reflect the real patient population. Healthy young donors with strong T cell fitness can make weak protocols look successful. Those same protocols can then fail with heavily pre-treated cancer patients whose immune systems are compromised.[5] Including Human Leukopak from older donors, patients with relevant health conditions, and people on immunosuppressive drugs helps catch protocol weaknesses before clinical manufacturing. Sanguine’s access to over 70,000 donors with diverse profiles supports building these development cohorts.

Comparing fresh and cryopreserved starting material is another key milestone. Fresh Human Whole Blood collections are logistically simpler for local manufacturing. Proving that cryopreserved starting material yields products that meet the required specs takes systematic testing across multiple donors and runs. Our standardized cryopreservation protocols reduce variability, supporting solid comparability data.

Biospecimen Requirements Across CAR-T Development Phases

Discovery and Target Validation Phase

The initial phase focuses on finding suitable tumor targets and engineering receptors with the best binding. It uses relatively small cell numbers but needs a range of specimen types to fully evaluate CAR function.

Essential Biospecimens for Discovery:

• Human CD3+ T Cells (5–20M cells per experiment) for CAR expression and basic function
• Human PBMCs (20–50M cells) for mixed lymphocyte reactions and specificity testing
• Target-positive tumor cell lines or patient-derived cells for cytotoxicity assays
• Human Plasma containing soluble target antigens for specificity validation
• Human CD56+ NK Cells as negative controls for antigen-specific killing
• Control Human Serum for complement-dependent cytotoxicity assessment
• Human Whole Blood for initial safety screening (cytokine release)

Key Quality Parameters:

• T cell viability ≥90% for consistent transduction efficiency
• Activation state documentation (CD25, CD69 expression)
• T cell receptor (TCR) diversity assessment via TRBV repertoire analysis
• Memory subset composition (naive, central memory, effector memory percentages)
• Donor serostatus for relevant pathogens
• Genomic annotation including age, sex, medication history
• Processing time from collection to cryopreservation <24 hours

Preclinical Development and Manufacturing Process Optimization

Moving from target validation to manufacturing protocol development needs larger cell numbers and more extensive characterization. Teams need to stress-test protocols across diverse patient scenarios.

Essential Biospecimens for Process Development:

• Human Leukopak (10–20 leukopaks) from healthy donors for baseline process establishment
• Human Leukopak (5–10 leukopaks) from disease-relevant populations (cancer patients, elderly, immunosuppressed)
• Matched Human Plasma from same donors for lot-matched plasma supplementation
• Human PBMCs from target patient population for potency assay development
• Human CD3+ T Cells for analytical method development and validation

Key Quality Parameters:

• TNC count consistency across leukopak lots (CV <30%)
• Mononuclear cell enrichment ≥90% post-density gradient separation
• CD4:CD8 ratio documentation for each lot
• Functional validation (proliferation, cytokine production) from each donor
• Complete genomic annotation enabling stratified analysis
• Full donor medical history including prior treatments
• Documented processing conditions and storage history

Clinical Manufacturing and Commercial Scale-Up

Clinical-stage manufacturing demands the highest standards, with full regulatory traceability. Every biospecimen component must meet pharmaceutical-grade standards and comprehensive testing to support regulatory submissions.

Essential Biospecimens for Clinical Manufacturing:

• Donor qualification per 21 CFR Part 1271 requirements
• Full infectious disease testing panel with documented results
• Certificates of analysis for all critical quality attributes
• Chain of custody documentation from collection through delivery
• Backup Human PBMCs for potency assay execution
• Reference Human CD3+ T Cells for assay qualification
• Human Plasma from matched donors for autologous culture supplementation

Key Quality Parameters:

• All FDA donor screening requirements met and documented
• Sterility assurance level appropriate for pharmaceutical manufacturing
• Endotoxin levels ≤0.5 EU/mL tested by LAL assay
• Complete batch records with traceability to donor
• Temperature monitoring throughout collection and transit
• Validated cryopreservation protocols with stability data
• Real-time release testing capabilities

Critical Success Factors in CAR-T Biospecimen Supply

Choosing the right vendor may be the single most important decision in CAR-T biospecimen sourcing. The provider needs to show operational maturity to support long-term supply through clinical development and, potentially, commercialization.[10] Regulatory inspections during review of a Biologics License Application look closely at starting material supplier qualifications. That makes vendor reliability especially important.

Backup supply options protect against disruptions that could delay trials or interrupt patient treatment. Qualifying multiple collection sites across the United States provides geographic redundancy while keeping quality consistent. Sanguine’s network spans major metropolitan areas and can quickly mobilize backup collection capacity.[11] This spread-out approach also makes things easier for patients in autologous collection scenarios.

Long-term supply agreements with flexible capacity help programs grow through uncertain phases. Early-phase trials may need 5–10 leukopaks a month, while Phase III trials can need hundreds of collections. A commercial launch can require thousands per year.[12] Providers who can scale up operations while keeping quality high are essential for programs aiming for commercial success. Our experience supporting programs from Phase I through commercial launch reflects this capability.

Autologous vs. Allogeneic Manufacturing: Biospecimen Implications

The autologous approach — where each patient is both donor and recipient — brings unique challenges compared to allogeneic, off-the-shelf approaches. Patients who need CAR-T have often gone through extensive prior treatment, including chemotherapy, radiation, and immunosuppression, all of which can weaken T cell fitness.[13] Low lymphocyte counts, T cell exhaustion, and altered immune status affect how well manufacturing succeeds and what the final product looks like.

Assessing the starting material is critical in autologous collection, to identify patients whose T cells might fail to manufacture properly. Flow cytometric analysis of Human Whole Blood before apheresis can predict outcomes, with absolute lymphocyte counts, CD4:CD8 ratios, and activation markers serving as useful early signals.[14] Pre-screening allows for better patient selection or lymphodepleting conditioning to improve collection yields.

Allogeneic approaches, which use healthy donor cells as universal starting material, change the requirements entirely. Building a master cell bank from carefully selected donors with optimal T cell traits enables consistent manufacturing.[15] Donor screening then expands to include HLA typing, TCR diversity assessment, and thorough genomic characterization. These qualified donors’ collections go through extensive sterility, endotoxin, mycoplasma, and adventitious agent screening before a lot is released.

Genomic Annotation: Predicting Manufacturing Success

How much clinical and phenotypic information comes with a biospecimen directly affects researchers’ ability to optimize protocols and predict product quality. Complete medication histories reveal exposure to immunosuppressants, corticosteroids, or chemotherapy that may affect T cell function and expansion.[16] Recent infection history flags donors whose immune systems may be activated or exhausted.

Lab values — complete blood counts, metabolic panels, immune subset counts — add quantitative context for interpreting outcomes. A patient with lymphopenia (absolute lymphocyte count <1000/μL) may need larger apheresis volumes.[17] Elevated inflammatory markers (CRP, ESR) suggest immune activation that could affect transduction efficiency or expansion. Sanguine’s genomic annotation captures these parameters, enabling manufacturing outcomes to be broken down by patient characteristics.

Collecting data over time throughout CAR-T trials reveals relationships between pre-manufacturing patient characteristics and clinical responses. Patients who successfully manufacture high-quality products may differ systematically from those who don’t. The differences can show up in prior treatment exposure, other health conditions, or baseline immune profile.[18] Providers who support longitudinal collection — from pre-apheresis baseline through post-infusion follow-up — make these analyses possible.

Laboratory Processing: From Apheresis to Cryopreserved Product

The processing steps from apheresis to a cryopreserved starting material introduce several variables that affect final quality. The anticoagulant used during apheresis — typically ACD-A or sodium citrate — impacts downstream processing and functional assays.[19] Delays between collection and cryopreservation must be kept short (ideally under 24 hours) to prevent activation, exhaustion, or cell death that would reduce yield.

Density gradient centrifugation remains the gold standard for enriching mononuclear cells from leukapheresis products. It separates lymphocytes and monocytes from granulocytes and red blood cells by density. Ficoll-Paque or an equivalent medium enables over 90% recovery of mononuclear cells with minimal granulocyte contamination.[20] But gradient centrifugation applies mechanical stress and osmotic shock that can activate cells if not carefully controlled. Standardized protocols — set g-forces, acceleration/deceleration profiles, and temperature control — keep quality consistent lot to lot.

How cells are frozen strongly affects how well they recover and function after thawing. Controlled-rate freezing at about 1°C per minute minimizes ice crystal formation. Cryoprotectant media (typically 10% DMSO with human serum albumin) protects against osmotic injury at the same time.[21] Storing in vapor-phase liquid nitrogen keeps cells intact during long-term banking. Sanguine’s validated protocols achieve over 85% post-thaw viability with function maintained across extended storage.

Donor Selection Strategies for CAR-T Development Programs

Choosing donors strategically has a big impact on research efficiency and manufacturing success. Healthy donor selection for process development should mirror the intended patient population in age, prevalence of other health conditions, and prior treatment exposure.[22] A therapy targeting elderly patients with multiply-relapsed lymphoma benefits from process development that uses age-matched, treatment-experienced donors, not just young healthy people.

HLA typing matters in both autologous and allogeneic settings. Autologous CAR-T doesn’t need HLA matching, since the donor and recipient are the same person. Allogeneic approaches, on the other hand, need to carefully consider HLA-related rejection.[23] Off-the-shelf products that use HLA deletion or modification require starting material from HLA-typed donors. Sanguine’s donor characterization includes HLA typing to support these requirements.

CMV status is another donor characteristic that’s often overlooked. People who are CMV-seropositive carry large populations of CMV-specific memory T cells. These cells can make up 10–20% of the total CD8+ compartment in some donors.[24] These experienced cells behave and function differently, which could affect how well CAR-T cells expand and persist. Controlling for CMV status during process development isolates this variable’s effect on manufacturing variability.

Quality Control Testing Throughout Development Pipeline

Thorough quality control at every phase protects research investment and speeds up timelines by catching problems early. Characterizing starting material should go well beyond viability to include functional testing, phenotype profiling, and sterility assurance.

Pre-Manufacturing Quality Assessment:

• Total and viable cell counts by automated cell counter
• Cell viability by flow cytometry (7-AAD or PI exclusion)
• Immunophenotyping: CD3, CD4, CD8, CD45RA, CCR7, PD-1, TIM-3
• T cell activation markers: CD25, CD69, HLA-DR
• Functional validation: anti-CD3/CD28 stimulation with proliferation assessment
• Cytokine production capacity: IFN-γ, TNF-α, IL-2 by ELISA or multiplex
• Sterility testing: 14-day bacterial and fungal cultures
• Mycoplasma testing by PCR
• Endotoxin quantification by LAL assay
• Transduction efficiency pilot with control vector

Post-Manufacturing Product Testing:

• CAR expression by flow cytometry (target ≥30% CAR+ cells)
• T cell subset composition in final product
• Residual vector analysis
• Expansion fold-change from starting material
• Viability and cell count for dose calculation
• Sterility and mycoplasma reconfirmation
• Endotoxin final product testing
• Identity testing confirming autologous source
• Potency assays: target-specific cytotoxicity, cytokine release
• Replication-competent lentivirus testing (if applicable)

Sanguine’s Integrated CAR-T Biospecimen Solutions

Our approach covers every phase from discovery through commercial manufacturing. Research-grade Human PBMCs and Human CD3+ T Cells support early target validation with consistent quality and fast turnaround. Process development teams get access to diverse Human Leukopak cohorts that represent the intended patient population.

Clinical-stage programs move to products collected under full FDA compliance with comprehensive regulatory documentation. Our Quality Management System maintains ISO 13485:2016 certification. From study design to receipt of samples, our scientific support team works with developers to define collection protocols, QC parameters, and documentation for regulatory submissions.[25]

Custom collection services can be tailored to study-specific needs, including specialized apheresis protocols, extended phenotypic characterization, or coordinated collection of matched plasma and cellular products. Our nationwide reach gives access to diverse donor populations and supports multi-site trials. Real-time inventory visibility and fast fulfillment (often same-day for fresh collections) support the demanding timelines of clinical cell therapy programs.

Emerging Trends in Cell Therapy Biospecimen Requirements

The field keeps evolving beyond classic CD19-targeted CAR-T, bringing new requirements. CAR-NK cells derived from Human CD56+ NK Cells offer potential advantages, including a lower risk of cytokine release syndrome and HLA-independent tumor recognition.[26] These modalities need distinct manufacturing protocols and specifications.

Tumor-infiltrating lymphocyte (TIL) therapy is another growing approach that requires specialized tissue biospecimens. While CAR-T sources cells from peripheral blood, TIL therapy starts with tumor tissue that provides tumor-reactive T cells.[27] Coordinating blood-derived collection (Human PBMCs, Human Plasma) with tissue collection supports comparing tumor-infiltrating and peripheral immune populations.

Regulatory expectations keep evolving too. Recent FDA guidance emphasizes manufacturing process validation, starting material specifications, and proving consistent product quality across runs.[28] Providers who stay ahead of these expectations set their customers up for success. Sanguine’s commitment to quality and regulatory foresight keeps our solutions compliant with current and upcoming requirements.

Geographic and Demographic Diversity in Cell Therapy Development

How diverse the biospecimen sourcing is directly affects whether CAR-T works well across different kinds of patients. Immune cell traits — subset frequencies, activation thresholds, cytokine production, exhaustion susceptibility — vary across demographic groups due to genetics and environment.[29] Therapies optimized only on cells from a narrow demographic may work less well in underrepresented populations.

Access to oncology biospecimens from demographically diverse cancer patients makes it possible to study ethnic disparities in manufacturing success and clinical response. African American patients with multiple myeloma, for example, show different disease biology and treatment response patterns than patients of European ancestry.[30] Process development that incorporates diverse biospecimens improves the odds that optimized protocols will work across a broad population.

Sanguine’s direct-to-donor model across the United States gives access to populations often left out of research — rural communities, non-English speaking populations, and patients with complex health conditions. This breadth supports health equity while practically improving the odds of broad commercial success.

---

Check Our Inventory

Accelerate your CAR-T and cell therapy development with premium-quality biospecimens at every research phase.

Explore our comprehensive oncology biospecimens inventory or contact our scientific team to discuss custom collection protocols tailored to your development needs.

Request a Custom Quote →

---

Ethical Sourcing and Regulatory Compliance

All Sanguine biospecimens are collected under IRB-approved protocols that ensure ethical treatment of donors and rigorous informed consent. Our HIPAA-compliant data systems protect donor privacy while giving researchers access to comprehensive genomic annotation. All products meet 21 CFR Part 1271 requirements for human cells and tissues, with full donor qualification documentation and infectious disease testing using FDA-licensed assays.

Quality certifications including ISO 9001:2015 and ISO 13485:2016 reflect our commitment to pharmaceutical-grade quality management. Every specimen is designated Research Use Only (RUO) unless specifically manufactured under clinical protocols, with clear documentation of intended use and regulatory status.

---

References

1. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365. doi:10.1126/science.aar6711
2. Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492-500. doi:10.1038/leu.2015.247
3. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545-553. doi:10.1056/NEJMoa1910607
4. Stroncek DF, Fellowes V, Pham C, et al. Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies. J Transl Med. 2004;2:23. doi:10.1186/1479-5876-2-23
5. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-571. doi:10.1038/s41591-018-0010-1
6. Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev. 2020;16:136-144. doi:10.1016/j.omtm.2019.11.018
7. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92-101. doi:10.1016/j.omtm.2016.12.006
8. Food and Drug Administration. Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). August 2007.
9. Benjamin R, Graham C, Yallop D, et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020;396(10266):1885-1894. doi:10.1016/S0140-6736(20)32334-5
10. Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018;53:164-181. doi:10.1016/j.copbio.2018.01.025
11. Lopes AG, Ip BC, Pritchett C, et al. Regional considerations for CAR-T therapy in lymphoma patients. Curr Hematol Malig Rep. 2021;16(2):161-169. doi:10.1007/s11899-021-00615-5
12. Abou-El-Enein M, Elsallab M, Feldman SA, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2(5):408-422. doi:10.1158/2643-3230.BCD-21-0084
13. Stein AM, Grupp SA, Levine JE, et al. Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells. CPT Pharmacometrics Syst Pharmacol. 2019;8(5):285-295. doi:10.1002/psp4.12388
14. Ghassemi S, Nunez-Cruz S, O’Connor RS, et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol Res. 2018;6(9):1100-1109. doi:10.1158/2326-6066.CIR-17-0405
15. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-117. doi:10.1038/nature21405
16. Garfall AL, Maus MV, Hwang WT, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373(11):1040-1047. doi:10.1056/NEJMoa1504542
17. Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621
18. Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26(12):1878-1887. doi:10.1038/s41591-020-1061-7
19. Stroncek DF, Lee DW, Ren J, et al. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. J Transl Med. 2017;15(1):59. doi:10.1186/s12967-017-1160-5
20. Kotlan B, Simsa P, Teillaud JL, et al. Novel methods for the analysis of antigen-specific T-cell immune responses in cancer patients. Cancer Immunol Immunother. 2004;53(8):707-718. doi:10.1007/s00262-003-0493-3
21. Perica K, Curran KJ, Brentjens RJ, Giralt SA. Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center. Biol Blood Marrow Transplant. 2018;24(6):1135-1141. doi:10.1016/j.bbmt.2018.02.018
22. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372-385. doi:10.1038/s41571-019-0184-6
23. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017;9(374):eaaj2013. doi:10.1126/scitranslmed.aaj2013
24. Pera A, Campos C, López N, et al. Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas. 2015;82(1):50-55. doi:10.1016/j.maturitas.2015.05.004
25. Roddie C, O’Reilly M, Dias Alves Pinto J, Vispute K, Lowdell M. Manufacturing chimeric antigen receptor T cells: issues and challenges. Cytotherapy. 2019;21(3):327-340. doi:10.1016/j.jcyt.2018.11.009
26. Rezvani K, Rouce R, Liu E, Shpall E. Engineering natural killer cells for cancer immunotherapy. Mol Ther. 2017;25(8):1769-1781. doi:10.1016/j.ymthe.2017.06.012
27. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62-68. doi:10.1126/science.aaa4967
28. Food and Drug Administration. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). Guidance for Industry. January 2020.
29. Nédélec Y, Sanz J, Baharian G, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell. 2016;167(3):657-669.e21. doi:10.1016/j.cell.2016.09.025
30. Costa LJ, Gonsalves WI, Kumar SK. Early mortality in multiple myeloma. Leukemia. 2015;29(9):1616-1618. doi:10.1038/leu.2015.122

Sanguine supplies research-grade human CD4+ T cells for studies like this.